<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1136">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 27, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01382017</url>
  </required_header>
  <id_info>
    <org_study_id>LCM-TMS-2010</org_study_id>
    <nct_id>NCT01382017</nct_id>
  </id_info>
  <brief_title>Effects of Lacosamide on Human Motor Cortex Excitability: a Transcranial Magnetic Stimulation Study</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Kiel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kiel</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medicinal Devices (BfArM)</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study has been designed to explore dose-depended effects of lacosamide (LCM) on motor
      cortex excitability with TMS in a randomized, double-blind, placebo-controlled crossover
      trial in young healthy human subjects, and to compare the pattern of excitability changes
      induced by LCM with those of carbamazepine (CBZ). LCM selectively enhances slow inactivation
      of voltage-gated sodium channel, and, in contrast to CBZ, does not affect steady-state fast
      inactivation (Errington et al., 2006). The enhancement of slow inactivation of sodium
      channels by LCM is a novel manner to modulate sodium channels and leads to normalization of
      activation thresholds and a reduced pathophysiological hyper-responsiveness, thereby
      effectively controlling neuronal hyperexcitability without affecting physiological activity
      (Beyreuther et al., 2007). Therefore, it is thought that LCM, compared to CBZ, will be
      better tolerated in clinical settings while being as or even more effective in controlling
      seizure activity. On the basis of the results from nonhuman studies, it is hypothesized that
      the TMS profile of LCM will be distinguishable from that of CBZ. CBZ, like other 'classical'
      sodium channel blockers such as phenytoin, predominantly demonstrated elevated TMS motor
      thresholds indicating reduced neuronal membrane excitability, without developing significant
      changes of synaptic intracortical inhibition and facilitation (Ziemann et al., 1996; Chen et
      al., 1997; Lee et al., 2005). Because of its novel mode of action it can only be speculated
      which TMS parameters LCM might affect. For example, more than exclusively affecting neuronal
      membrane excitability, LCM could possibly also affect inhibitory mechanisms such as short-
      and long-latency intracortical inhibition (Valls-Sole et al., 1992; Kujirai et al., 1993).
      This would in line with other well-tolerated modern antiepileptic drugs (Ziemann et al.,
      1996; Reis et al., 2002; Lang et al., 2006).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>TMS measures of cortical excitability</measure>
    <time_frame>within 24h after intake of study medication</time_frame>
    <safety_issue>No</safety_issue>
    <description>Transcranial magnetic stimulation (TMS) measurements included resting motor thresholds (RMT) and active motor thresholds (AMT), the intensity to evoke MEP of âˆ¼1mV peak-to-peak amplitude (SI1mV), short-interval intracortical inhibition/intracortical facilitation (SICI/ICF), long-interval intracortical inhibition (LICI), short-interval intracortical facilitation (SICF), recruitment curves, MEP under tonic activation (aMEP), and cortical silent period (CSP), and MEP changes in response to short trains of repetitive TMS.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Healthy Male Volunteers</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lasosamide 200</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lacosamide 200 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lacosamide 400</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lacosamide 400 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carbamazepine 600</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Carbamazepine 600 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lacosamide</intervention_name>
    <description>Lacosamide 200 or 400 mg</description>
    <arm_group_label>Lasosamide 200</arm_group_label>
    <arm_group_label>Lacosamide 400</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carbamazepine</intervention_name>
    <description>Carbamazepine 600 mg</description>
    <arm_group_label>Carbamazepine 600</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy

          -  male

          -  right-handed

          -  aged 18-45 years

        Exclusion Criteria:

          -  cardiac pacemaker

          -  metal implants in the head

          -  intake of any medication

          -  previous neurologic, psychiatric, or chronic internal diseases

          -  pregnancy or breastfeeding; drug, nicotine, or alcohol abuse

          -  known or expected intolerance to soy beans, peanuts, LCM or CBZ; abnormal ECG with
             prolonged PQ-interval

          -  participation in another clinical trial within the previous 8 weeks
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas Lang, PD Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Christian-Albrechts University Kiel, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Departmenr of Neurology, UKSH Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.uksh.de/neurologie-kiel</url>
    <description>Department of Neurology, University of Kiel, Germany</description>
  </link>
  <verification_date>August 2012</verification_date>
  <lastchanged_date>August 28, 2012</lastchanged_date>
  <firstreceived_date>June 23, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Kiel</investigator_affiliation>
    <investigator_full_name>Nicolas Lang</investigator_full_name>
    <investigator_title>PD Dr. med.</investigator_title>
  </responsible_party>
  <keyword>lacosamide</keyword>
  <keyword>carbamazepine</keyword>
  <keyword>placebo</keyword>
  <keyword>transcranial magnetic stimulation</keyword>
  <keyword>TMS</keyword>
  <keyword>motor cortex</keyword>
  <keyword>sodium channel</keyword>
  <keyword>inhibition</keyword>
  <keyword>threshold</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carbamazepine</mesh_term>
    <mesh_term>Lacosamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
